We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Join Seminar at Campus Gasthuisberg

Join the free seminar conducted on Real-Time Cell Viability Apoptosis and on Human iPSC-Derived Cell Types:

  • Campus Gasthuisberg I Room 04.330, O&N4 I Herestraat 49, 3000 Leuven Room 04.330, Onderwijs en Navorsing 4, Campus Gasthuisberg.
  • Date: Wednesday, September 27, 2017
  • Time: 9:30 AM–11:30 AM (CEST: Amsterdam, Berlin, Stockholm)

Contact: Lindsay Mesure lindsay.mesure@promega.com

Join the complimentary onsite seminar at Campus Gasthuisberg on 27 September 2017

The program will be presented by both a scientist from Promega and from Cellular Dynamics International - a FUJIFILM company

TIME: 9:30-10:30

Title: Utilizing a Novel Engineered Shrimp-Derived Luciferase to Enable Real-Time In Vitro Measurement of Cell Viability and Apoptosis using a Plate-Reading Luminometer

Speaker: Dr. Terry Riss (Global Strategic Manager Cell Health, Promega Corporation) 


We have engineered two versions of a shrimp-derived luciferase to develop new in vitro assay technologies for toxicological research. The first version of this new technology uses an engineered luciferase and a pro-substrate as a reagent to monitor cell viability in real-time by measuring the conversion of the pro-substrate into a luciferase substrate which is limited to live cells. Viable cell number is monitored by recording luminescence repeatedly from the same sample of cells for days, providing kinetic information on the status of the culture. The real-time viability assay also provides a new tool to enable repeated dose toxicity experiments extending for weeks. Assay reagent can be delivered to cultures and viable cell number recorded just prior to the normal schedule of changing culture medium and replenishing the toxin of interest. The reagents are well tolerated by live cells which enables subsequent multiplexing of other assays such as extraction of RNA to analyze gene expression to identify specific stress response pathways. The second version uses small and large fragments of luciferase that have been engineered as fusion proteins linked to annexin V for detecting of apoptosis in real-time using a plate-reading luminometer. The individual annexin V-luciferase fragment fusion pairs have low intrinsic affinity for each other and thus produce no or low luminescence in culture medium or in the presence of non-apoptotic cells; but, when the annexin V-luciferase fragment fusion proteins bind in close proximity to phosphatidylserine exposed on the surface of apoptotic cells, the luciferase fragments can reconstitute an active enzyme and generate a luminescent signal. The annexin v-luciferase fragment fusion proteins and a luciferase substrate are combined to form a reagent that is added directly to cells in culture to create a homogeneous protocol that does not require cell washing steps typically used with fluorescent annexin V binding assays. Monitoring luminescence over time shows the onset of apoptosis precedes secondary necrosis measured from the same sample by multiplexing with a non-permeable fluorogenic DNA binding dye to indicate membrane integrity. These new luciferase assay technologies to monitor cell viability and apoptosis in real-time from the same samples provide kinetic information not available from endpoint assays and greatly simplify assay protocols compared to using flow cytometry or high content imaging.

TIME: 10.30-11.30

Title: Human iPSC-Derived Cell Types Enable Investigation of  Molecular Mechanisms and Prediction of Drug Liabilities in Physiologically Relevant In Vitro Models.

Speaker: Giorgia Salvagiotto, Ph.D Senior Field Application Scientist, Cellular Dynamics International - a FUJIFILM company 


Human cell types differentiated from induced pluripotent stem cells (iPSCs) offer an attractive source of cellular material for both basic research and drug discovery because of the biologically relevant systems they can represent in vitro. The iPSC technology is a key element for modeling human biology in a dish, which is otherwise difficult to explore using conventional cell lines, primary cells, or animal models. Our approach is to generate iPSC-derived cell types with high quality, purity, and unlimited quantities, design relevant assays with cells derived from apparently healthy donors, and develop disease models using environmental stimuli or disease-specific, patient-derived cells.


The presentation will focus on two iPSC-derived cell types, neurons and cardiomyocytes, their characterization, and their functional utility to study disease mechanisms or detect drug liabilities. In particular, we will discuss examples of applications of iPSC-derived neurons to model neurodegenerative diseases and neuropathy, including chemotherapy-induced neuropathy (CIPN). These diseases are difficult to study due to the lack of human models. We will show that the iPSC-derived neurons display the phenotypic characteristics of the disease in vitro, and offer the relevant sensitivity to detect drug neurotoxicity at clinical relevant concentrations. Similarly, we will present case studies that show how iPSC-derived cardiomyocytes could potentially be included in early detection of cardiac liability across different therapeutic classes, including anti-cancer drugs such as kinase inhibitors and monoclonal antibodies.


These advances in iPSC technology provide access to previously unattainable human cell types opening new opportunities to address the limitations of rodent primary cells and immortalized cell lines.

Share With a Friend

We will NOT sell your personal information, such as your name or email address, to third parties or use your email address to send you marketing materials. The email and names entered will only be used to identify the sender and recipient of the email.

Send Cancel